← Back to Search

Electrical Stimulation for Total Knee Replacement Recovery

Phase 1

Waitlist Available

Led By Lynn Snyder-Mackler, PT, ScD

Research Sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

TKA for unilateral tricompartmental knee OA

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing whether electrical stimulation can help people recover quadriceps strength and function after a knee replacement surgery.

Who is the study for?

This trial is for individuals who have had a total knee replacement due to osteoarthritis. Participants should not have insulin-dependent diabetes, other lower limb orthopedic issues affecting function, neurological conditions, or a BMI over 40.Check my eligibility

What is being tested?

The study tests if high-level neuromuscular electrical stimulation alongside early intensive rehabilitation can improve quadriceps strength and overall function after a primary total knee arthroplasty (TKA).See study design

What are the potential side effects?

While the document doesn't specify side effects, electrical stimulation may cause discomfort, skin irritation at the electrode sites, muscle fatigue or soreness.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am having a total knee replacement for arthritis in all three compartments of one knee.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Functional Tests

Quadriceps Activation

Quadriceps Strength

Secondary outcome measures

Self reports of function

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Lead Sponsor

1,963 Previous Clinical Trials

2,674,541 Total Patients Enrolled

National Center for Medical Rehabilitation Research (NCMRR)NIH

2 Previous Clinical Trials

79 Total Patients Enrolled

Lynn Snyder-Mackler, PT, ScDPrincipal InvestigatorUniversity of Delaware

Media Library

Treatment Clinical Trial Eligibility Overview. Trial Name: NCT00224913 — Phase 1

Total Knee Replacement Research Study Groups:

Total Knee Replacement Clinical Trial 2023: Treatment Highlights & Side Effects. Trial Name: NCT00224913 — Phase 1

Treatment 2023 Treatment Timeline for Medical Study. Trial Name: NCT00224913 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who can be considered eligible for participation in this investigation?

"In order to be accepted into this medical trial, potential participants should have arthrosis and a current age between 45 and 85. Approximately 200 patients are required for the study's completion."

Answered by AI

Does the age of 55+ preclude individuals from participating in this medical trial?

"The stated parameters for this research trial necessitate that participants are aged between 45 and 85."

Answered by AI

Are there any open enrollment opportunities for potential participants of this clinical trial?

"The data hosted on clinicaltrials.gov indicates that this particular medical trial, which was initially published on March 1st 2002, is no longer actively recruiting participants. Nevertheless, 648 other trials are currently seeking patients to join their study."

Answered by AI

Has this therapeutic intervention been validated by the FDA?

"Due to the early stage of testing, our team has assigned this treatment an estimated safety rating of 1. This is because Phase 1 trials provide limited information regarding efficacy and safety."

Answered by AI